Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Centessa Pharmaceuticals plc Director's Dealing 2024

Jan 3, 2024

31309_dirs_2024-01-02_6a95af4f-b721-40fa-b657-4b61e6add48f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2023-12-31

Reporting Person: Weinhoff Gregory M (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-12-31 Ordinary Shares F 11742 $7.96 Disposed 257097 Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.